Kusajili – Centralise les essais cliniques mondiaux

Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in subjects with active Ulcerative Colitis (UC).

• Pays Australia, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Netherlands, New Zealand, Poland, Russian Federation, Ukraine, United States,
• Organes Aucun
• Spécialités Aucun

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.

• Pays Austria, Bulgaria, Canada, Czech Republic, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.

• Pays Belgium, Canada, Czech Republic, France, Hungary, Italy, Poland, United States,
• Organes Aucun
• Spécialités Aucun

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.

• Pays Belgium, Canada, Czech Republic, France, Hungary, Poland, Romania, Turkey,
• Organes Aucun
• Spécialités Aucun

A Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids This study is being conducted in patients taking glucocorticoids for treatment of various diseases. It is a 2-year study that will compare the effects of denosumab and risedronate.

• Pays Argentina, Belgium, Canada, Colombia, Czech Republic, Denmark, France, Germany, Hungary, Korea, Republic of, Mexico, Netherlands, Poland, Russian Federation, Spain, United States,
• Organes Aucun
• Spécialités Aucun